134 related articles for article (PubMed ID: 10226793)
1. Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration.
Prahalada S; Block G; Handt L; DeBurlet G; Cahill M; Hoe CM; van Zwieten MJ
Horm Metab Res; 1999; 31(2-3):133-7. PubMed ID: 10226793
[TBL] [Abstract][Full Text] [Related]
2. Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation.
Schleim KD; Jacks T; Cunningham P; Feeney W; Frazier EG; Niebauer GW; Zhang D; Chen H; Smith RG; Hickey G
Endocrinology; 1999 Apr; 140(4):1552-8. PubMed ID: 10098487
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Murphy MG; Bach MA; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz BJ
J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
[TBL] [Abstract][Full Text] [Related]
5. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
Jacks T; Smith R; Judith F; Schleim K; Frazier E; Chen H; Krupa D; Hora D; Nargund R; Patchett A; Hickey G
Endocrinology; 1996 Dec; 137(12):5284-9. PubMed ID: 8940347
[TBL] [Abstract][Full Text] [Related]
6. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles.
Hickey GJ; Jacks TM; Schleim KD; Frazier E; Chen HY; Krupa D; Feeney W; Nargund RP; Patchett AA; Smith RG
J Endocrinol; 1997 Feb; 152(2):183-92. PubMed ID: 9071975
[TBL] [Abstract][Full Text] [Related]
7. GH, IGF-I, IGFBP-3 and IGFBP-2 in cerebrospinal fluid of infants, during puberty and in adults.
Heinze E; Böker M; Blum W; Behnisch W; Schulz A; Urban J; Mauch E
Exp Clin Endocrinol Diabetes; 1998; 106(3):197-202. PubMed ID: 9710360
[TBL] [Abstract][Full Text] [Related]
8. Tissue-specific alterations in insulin-like growth factor-I concentrations in response to 3,3',5-triiodo-L-thyronine supplementation in the growth hormone receptor-deficient sex-linked dwarf chicken.
Vasilatos-Younken R; Dunnington EA; Siegel PB; McMurtry JP
Gen Comp Endocrinol; 1997 Jan; 105(1):31-9. PubMed ID: 9000465
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin a treatment is able to revert the decrease in circulating GH and IGF-I and the increase in IGFBPs induced by adjuvant arthritis.
Soto L; Martín AI; Vara E; López-Calderón A
Horm Metab Res; 2001 Oct; 33(10):590-5. PubMed ID: 11607878
[TBL] [Abstract][Full Text] [Related]
10. Effect of pulsatile growth hormone administration to the growth-restricted fetal sheep on somatotrophic axis gene expression in fetal and placental tissues.
Bloomfield FH; van Zijl PL; Bauer MK; Phua HH; Harding JE
Am J Physiol Endocrinol Metab; 2006 Aug; 291(2):E333-9. PubMed ID: 16507606
[TBL] [Abstract][Full Text] [Related]
11. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
Svensson J; Ohlsson C; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Baylink D; Mohan S; Bengtsson BA
J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080
[TBL] [Abstract][Full Text] [Related]
12. The effect of epidermal growth factor on circulating levels of free and total IGF-I and IGF-binding proteins in adult rats.
Frystyk J; Vinter-Jensen L; Skjaerbaek C; Flyvbjerg A
Growth Regul; 1996 Mar; 6(1):48-54. PubMed ID: 8717450
[TBL] [Abstract][Full Text] [Related]
13. Differential responses of the growth hormone axis in two rat models of streptozotocin-induced insulinopenic diabetes.
Kim E; Sohn S; Lee M; Jung J; Kineman RD; Park S
J Endocrinol; 2006 Feb; 188(2):263-70. PubMed ID: 16461552
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
Chapman IM; Bach MA; Van Cauter E; Farmer M; Krupa D; Taylor AM; Schilling LM; Cole KY; Skiles EH; Pezzoli SS; Hartman ML; Veldhuis JD; Gormley GJ; Thorner MO
J Clin Endocrinol Metab; 1996 Dec; 81(12):4249-57. PubMed ID: 8954023
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
[TBL] [Abstract][Full Text] [Related]
16. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
Copinschi G; Van Onderbergen A; L'Hermite-Balériaux M; Mendel CM; Caufriez A; Leproult R; Bolognese JA; De Smet M; Thorner MO; Van Cauter E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2776-82. PubMed ID: 8768828
[TBL] [Abstract][Full Text] [Related]
17. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Murphy MG; Plunkett LM; Gertz BJ; He W; Wittreich J; Polvino WM; Clemmons DR
J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and toxicological effects of chronic porcine growth hormone administration in dogs.
Prahalada S; Stabinski LG; Chen HY; Morrissey RE; De Burlet G; Holder D; Patrick DH; Peter CP; van Zwieten MJ
Toxicol Pathol; 1998; 26(2):185-200. PubMed ID: 9547855
[TBL] [Abstract][Full Text] [Related]
19. The effect of the frequency of subcutaneous insulin-like growth factor-1 administration on weight gain in growth hormone deficient mice.
Woodall SM; Breier BH; O'Sullivan U; Gluckman PD
Horm Metab Res; 1991 Dec; 23(12):581-4. PubMed ID: 1778592
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone (GH) and insulin-like growth factor I responses after treatments with an orally active GH secretagogue L-163,255 in swine.
Chang CH; Rickes EL; McGuire L; Frazier E; Chen H; Barakat K; Nargund R; Patchett A; Smith RG; Hickey GJ
Endocrinology; 1996 Nov; 137(11):4851-6. PubMed ID: 8895356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
